

**REMARKS/ARGUMENTS**

Claims 9-11, 14 and 16-17 are currently pending.

Applicants would like to thank the Examiner for her time during the telephone conversation on January 10, 2007. As discussed, applicants have represented the claims in this supplemental amendment as they were presented March 27, 2006. It is applicants understanding that this format is acceptable to the Examiner. With respect to the Examiner's request that we identify the amino acid in position 2042 for SEQ ID NOS: 2, 4, 5, 6, 7 and 25, please see the table below. Position 2042 is amino acid position 1233 in the sequence listings.

SEQ ID NO.	AMINO ACID
2	Cys
4	Cys
5	Cys
6	Arg
7	Cys
25	Cys

Application No. 10/789,355  
Supplemental Response dated January 16, 2007

It is respectfully submitted that the subject application is in condition for allowance and such favorable action at an early date is earnestly solicited. If the Examiner feels that a telephone interview would be helpful in advancing prosecution of this application, the Examiner is invited to contact the attorney below.

Respectfully submitted,

/Paula K. Wittmayer/  
Paula K. Wittmayer, Reg. No. 53,785  
Attorney for Applicant(s)

Patent Department  
Boehringer Ingelheim Corp.  
900 Ridgebury Road  
P.O. Box 368  
Ridgefield, CT 06877  
Tel.: (203) 791-6692  
Date: January 16, 2007